NIUM

Company profile

NIUM company profile

The gut microbiome plays a crucial role in health and disease, yet existing models for studying microbiome interactions are slow, expensive, and unreliable. Current in-vitro systems lack scalability and physiological accuracy, while clinical trials are costly and impractical for early-stage R&D. This bottleneck limits innovation in food, nutrition, and pharma, preventing companies from efficiently testing and developing microbiome-targeted products. NIUM solves this with the first fully automated, scalable gut-microbiome-on-a-chip platform, enabling cost-effective, high-throughput testing at lower cost with superior reproducibility.